Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suxiao Jiuxin Pill for acute ST-segment elevation myocardial infarction
ChiCTR2400080278Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- Jan 2024
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Suxiao Jiuxin Pills in myocardial infarction (MI) (3 arms), sponsored by Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoint: Incidence of composite endpoint events including MACCE at 2 years after myocardial infarction. Started Jan 2024; status: recruiting.
02
Drugs
Suxiao Jiuxin Pills
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2400080278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080278.